Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. researchers have developed prodrugs acting as apoptosis regulator Bcl-2 inhibitors reported to be useful for the treatment of cancer, particularly chronic myeloid leukemia.